Home > Oncology > ASCO 2022 > Haematologic Malignancies > Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma

Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma

Presented by
Prof. Juan Du, Shanghai Chang Zheng Hospital, China
Conference
ASCO 2022
Doi
https://doi.org/10.55788/3210a094

GC012F, a dual CAR-T therapy, showed favourable safety outcomes and a high response rate in a population of patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM) in an update of the first-in-human study testing this BCMA/CD19-targeting therapy.

“FasTCAR GC012F is a CAR-T therapy that targets both BCMA and CD19 in order to establish fast, deep, and durable responses in patients with MM,” explained Prof. Juan Du (Shanghai Chang Zheng Hospital, China). With a time from isolation until freezing of only 22–36 hours, the current therapy establishes a fast vein-to-vein time, potentially eliminating the need for a bridging therapy prior to CAR-T infusion, which is often needed in conventional CAR-T therapy. The current, open-label, single arm, investigator-initiated trial subjected 28 patients with heavily pre-treated (≥3 lines of therapy) RRMM to GC012F dual CAR-T therapy. Safety was the primary endpoint of this study. Of note, 89% of the patients had a high-risk profile.

According to Prof. Du, the safety profile of the CAR-T therapy was favourable. Grade ≥3 haematologic adverse events ranged from 36% for anaemia to 82% for neutropenia. The cases of cytokine release syndrome were mostly low grade (0–2: 93%) and only 2 patients experienced a grade 3 cytokine release syndrome event. No cases of immune effector cell-associated neurotoxicity syndrome were reported.

In total, an impressive 89.3% of the patients responded to the therapy, with 75% of the patients displaying a minimal residual disease (MRD) complete response or stringent complete response and 86% of the patients demonstrating a very good partial response (VGPR) or better. In addition, after a median follow-up of 6.3 months, the median duration of response was not reached.

Prof. Du summarised that the updated results of this first-in-human study assessing FasTCAR GC012F dual CAR-T therapy showed very promising activity in a heavily pre-treated, high-risk population of patients with RRMM, with a favourable safety profile. “Fast, deep, and durable responses were achieved with this novel CAR-T therapy.”

  1. Du J, et al. Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). Abstract 8005, ASCO 2022 Annual Meeting, 3–7 June, Chicago, IL, USA.

Copyright ©2022 Medicom Medical Publishers



Posted on